EcoDrugPlus

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSDLAG00005018520
Gene Symbol: DNMT1
1 Cross references
212 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSDLAG00005011832
Gene Symbol: TOP1
1 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSDLAG00005010532
Gene Symbol: TOP2B
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSDLAG00005004446
Gene Symbol: TOP1A
1 Cross references
208 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSDLAG00005000924
Gene Symbol: EPHA3
1 Cross references
211 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSDLAG00005004742
Gene Symbol: FYNA
1 Cross references
192 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSDLAG00005010553
Gene Symbol: FYNB
1 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSDLAG00005034909
Gene Symbol: GPR84
1 Cross references
124 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSDLAG00005007005
Gene Symbol: HCK
1 Cross references
203 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSDLAG00005008355
Gene Symbol: ITK
1 Cross references
208 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSDLAG00005002664
Gene Symbol: IMPDH2
1 Cross references
202 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSDLAG00005025117
Gene Symbol: JAK1
1 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).